Commodore Capital’s Enliven Therapeutics ELVN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q3
$96.1M Hold
2025
Q2
$94.1M Buy
2025
Q1
$92M Buy
2024
Q4
$94.6M Buy
2024
Q3
$105M Buy
2024
Q2
$92.9M Hold
2024
Q1
$69.9M Buy
2023
Q4
$40.2M Hold
2023
Q3
$39.6M Buy
2023
Q2
$47.9M Buy
2023
Q1
$37.9M Buy
2022
Q4
$10.2M Buy